{(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate hydrochloride | 1425926-03-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate hydrochloride
• 英文别名: {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate hydrochloride salt；[(1S,2S,4R)-4-[6-[[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino]pyrimidin-4-yl]oxy-2-hydroxycyclopentyl]methyl sulfamate;hydrochloride
• CAS: 1425926-03-9
• 化学式: C₂₀H₂₅ClN₄O₆S*ClH
• 分子量: 521.422
• InChiKey: RHYUCTLCIULPOJ-MVWDVHKDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.01
• 重原子数：
  33
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  154
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  4-((1R,3S,4S)-3-(benzyloxy)-4-(benzyloxymethyl)cyclopentyloxy)-6-chloropyrimidine 在 N-甲基吡咯烷酮 、 盐酸 、 三氯化硼 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 130.0 ℃ 、344.75 kPa 条件下， 反应 67.0h， 生成 {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate hydrochloride
  参考文献：
  名称：

  [EN] INHIBITORS OF NEDD8-ACTIVATING ENZYME
  [FR] INHIBITEURS DE L'ENZYME ACTIVANT NEDD8

  摘要：

  公开号：

  WO2013028832A3

文献信息

• Inhibitors of nedd8-activating enzyme
  申请人：IP Gesellschaft für Management mbH

  公开号：EP2764866A1

  公开（公告）日：2014-08-13

  The invention relates to an administration unit comprising crystalline form I of (1 S,2S,4R)-4-[(6-[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.

  该发明涉及一种包含晶型I的(1S,2S,4R)-4-[(6-[(1R,2S)-5-氯-2甲氧基-2,3-二氢-1H-茚-1-基]氨基}嘧啶-4-基)氧基]-2-羟基环戊基}甲基磺酰胺(I-216)盐酸盐的管理单元，以及包括该管理单元的包装。
• INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF
  申请人：ADT PHARMACEUTICALS, INC.

  公开号：US20160168113A1

  公开（公告）日：2016-06-16

  Disclosed are compounds, for example, compounds of formula I, wherein R, R 0 , R 1 -R 8 , n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition, for example, cancer.

  揭示了化合物，例如，具有公式I的化合物，其中R、R0、R1-R8、n、X、Y、Y′和E如本文所述，包含这些化合物的药物组合物，以及治疗或预防疾病或病症的方法，例如癌症。
• METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES
  申请人：ADT PHARMACEUTICALS, INC.

  公开号：US20160168108A1

  公开（公告）日：2016-06-16

  Disclosed are compounds, for example, a compound of formula I, wherein R, R 0 , R 1 -R 8 , n, X, Y, Y′, and E are as described herein, pharmaceutical compositions containing such compounds, and methods of treating or preventing a disease or condition for example, cancer, mediated by the ras gene.

  揭示了化合物，例如，公式I的化合物，其中R、R0、R1-R8、n、X、Y、Y′和E如本文所述，包含这些化合物的药物组合物，以及治疗或预防疾病或状况的方法，例如由ras基因介导的癌症。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES DE TRAITEMENT DU CANCER
  申请人：ADT PHARMACEUTICALS INC

  公开号：WO2017106520A1

  公开（公告）日：2017-06-22

  Disclosed are compounds of formulas I and II, in which R, R0, R1-R4, R7-R10, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds. The compounds and pharmaceutical compositions are for use in treating or preventing diseases, for example, cancer.

  公开了具有I和II式的化合物，其中R、R0、R1-R4、R7-R10、n、X、Y、Y'和E如本文所述，以及含有这些化合物的药物组合物。这些化合物和药物组合物用于治疗或预防疾病，例如癌症。
• [EN] THYCLOTIDES<br/>[FR] THYCLOTIDES
  申请人：US HEALTH

  公开号：WO2021211786A1

  公开（公告）日：2021-10-21

  Disclosed are thyclotides, which are oligomers, each comprising (a) from about 8 to about 25 monomer units of formula (I) and (b) from 0 to about 24 monomer units of formula (II): wherein B is a nucleobase, which can be the same or different at each occurrence, or a pharmaceutically acceptable salt thereof. The thyclotides are soluble in water, bind strongly to complementary DNA and RNA, and are cell permeable. The thyclotides are useful as reagents for antisense and antigene applications, and as probes in molecular diagnostics and microarrays.

  本发明涉及一种称为thyclotides的寡聚体，每个寡聚体包括(a)约8到约25个式(I)的单体单位和(b)约0到约24个式(II)的单体单位：其中B是核碱基，可以在每次出现时相同或不同，或其药学上可接受的盐。这些thyclotides在水中溶解，能够强烈结合互补的DNA和RNA，并且具有细胞穿透性。这些thyclotides可用作反义和抗基因应用的试剂，以及分子诊断和微阵列中的探针。